Chinese technology company MegaRobo Technologies has raised nearly $200 million in a new financing round joined by the Oman Investment Authority, the sovereign wealth fund of the Sultanate of Oman, Bloomberg reported on November 19, 2026. The company announced the round in a statement dated November 18, and said the money will support continued investment in its core technology, the global expansion of its AI for Science business, and infrastructure that lets artificial intelligence operate in complex physical environments. The round brings MegaRobo's total funding to approximately $600 million across multiple financing rounds, and it arrives as the company waits in the queue for a Hong Kong listing it filed for in mid-2025. MegaRobo did not disclose its valuation in the new round, and its statement names no lead investor and gives the round no letter designation.
What MegaRobo builds
MegaRobo describes itself as a technology company building what it calls Intelligence Infrastructure for the Physical World. In plain terms, it builds robotic laboratories and the software that runs them, so that drug research and other scientific work can be designed, executed, and observed by machines under the direction of AI systems. The company is based in Suzhou, China, and was founded in 2016. Its pitch is that the first generation of AI learned from digital information — text, images, video, and code — while the next generation will learn by acting on the physical world, running experiments, observing what happens, and using those results to decide what to try next.
That framing puts MegaRobo in the middle of two large trends at once. The first is lab automation, where robots handle the repetitive physical work of science: moving samples, running assays, and operating instruments around the clock. The second is AI for Science, where machine learning models propose experiments, predict molecular structures, and screen drug candidates. MegaRobo's argument is that neither half is enough on its own. A model that can design a molecule but cannot test it is guessing, and a robot that can run an experiment but cannot learn from the result is just a faster pair of hands. The company says its systems close that loop, connecting reasoning, design, execution, observation, and learning in a single cycle.
The company says it has delivered products and technologies to more than 500 customers, including leading global pharmaceutical companies, drug discovery organizations, biotechnology companies, and research institutions. Its systems support key stages of discovery and development, including early research, target and mechanism discovery, drug screening, and candidate optimization. That customer count matters because it separates MegaRobo from pure research-stage AI drug discovery startups that have impressive models but few paying users. A lab automation business sells instruments and systems that laboratories already budget for, which gives it revenue to fund the longer AI bets.
The funding round
The new round is worth nearly $200 million, and MegaRobo was careful to frame the figure exactly that way in its own announcement — nearly $200 million, not $200 million. The distinction is worth keeping, because the company has not published an exact figure, and rounding up would overstate what is actually known. The round was joined by the Oman Investment Authority as a new investor, along with CMB International, also new. Existing investors Asia Investment Capital, Granite Asia, and Sinovation Ventures all put in more money. The company did not name a lead investor, and Bloomberg reported that the company's statement does not confirm one, even though data provider Dealroom described the Omani fund as the lead.
The mix of investors tells its own story. Asia Investment Capital and Granite Asia co-led MegaRobo's earlier Series C, so their participation here is a continuation of a long relationship rather than a new bet. Sinovation Ventures, the firm founded by Kai-Fu Lee, has backed the company through multiple stages. The new names are the ones that change the picture. CMB International is the investment arm connected to China Merchants Bank, a major Chinese financial institution. The Oman Investment Authority is something else entirely: a sovereign wealth fund from the Gulf, deploying state capital into a Chinese technology company at a moment when cross-border technology investment is under more scrutiny than at any point in the past decade.
MegaRobo said the proceeds will go to three things: continued investment in core technology, the global expansion of its AI for Science business, and the development of infrastructure that enables AI to operate in increasingly complex physical environments. The company did not break down how the money will be split between those three, and Bloomberg did not report further detail on which markets it is targeting. That leaves the most interesting question — where exactly the global expansion lands — unanswered for now, though the company's own statement points to continued expansion across North America, Europe, the Middle East, and Asia.
Who the Oman Investment Authority is
The Oman Investment Authority, usually shortened to OIA, manages the funds and assets of the Sultanate of Oman as the country's sovereign wealth fund. Sovereign wealth funds are state-owned investment vehicles that deploy a country's surplus revenues, often from energy exports, into assets around the world. Oman's fund is smaller and less famous than its neighbours in Abu Dhabi, Qatar, or Saudi Arabia, but it has been steadily building a portfolio that includes technology, and its appearance in a Chinese AI round is a signal worth reading carefully.
For MegaRobo, an Omani sovereign investor brings more than money. It brings a relationship with a Gulf state that is itself investing heavily in technology and diversification away from oil, and it opens a plausible path to customers, partnerships, and expansion in the Middle East. The company's statement explicitly lists the Middle East among the regions where its expansion will accelerate, and a sovereign fund from the region is the most direct possible bridge into that market. For the OIA, the investment is a stake in a company working on one of the most strategically important applications of AI — the automation of scientific discovery — at a valuation that, whatever it is, has not been disclosed.
The deal also fits a wider pattern of Gulf capital flowing into AI. Sovereign funds from the region have become some of the most active large investors in artificial intelligence infrastructure, models, and applications, and they have shown a willingness to invest across geopolitical lines that private Western venture firms sometimes avoid. A Chinese lab automation company with real customers, real revenue, and a credible path to a public listing is exactly the kind of asset that appeals to a fund looking for exposure to AI's physical layer rather than another chatbot. The fact that the OIA chose to join this round, rather than a consumer AI company, says something about where sophisticated state capital thinks the durable value in AI will sit.
AI for Science and the One Intelligence Stack
MegaRobo's product story is built around a concept it calls the One Intelligence Stack, a single reusable technology foundation that connects models and agents, data, workflows, software, scientific instruments, robotics, automation, and real-world feedback. The company describes the loop in five steps: think, design, execute, observe, learn. An AI system reasons about a scientific problem, designs an experiment, executes it in an automated laboratory, observes the results, and learns from what happened, feeding that learning into the next cycle. Science, the company argues, is the first proving ground for this architecture because discovery depends on exactly that loop, often under conditions where the answer is not known in advance.
The most concrete expression of that idea is Megalaxy Lab, the company's platform for making real-world experimentation programmable. Researchers and AI agents can configure experiments, route them to automated laboratory systems, track execution, and receive structured, machine-readable results that feed directly into the next cycle of scientific reasoning. Megalaxy Lab has served more than 200 customers, according to the company. That is a meaningful number, because it suggests the platform is not a demo but a working service that laboratories rely on, and because every experiment run through it generates the kind of structured data that makes the next generation of models better.
MegaRobo is also trying to turn that capability into a shared benchmark for the field. Together with industry partners including Tencent Cloud and Twist Bioscience, the company has launched Poreva Open, a global AI protein design challenge open to all models and technical approaches. Megalaxy Lab will provide wet-lab validation for more than 10,000 protein design sequences, giving innovators worldwide a chance to test their models against real experimental results. The aim is to establish a common benchmark for AI-driven protein design, and to shift scientific infrastructure from work organized as individual projects toward experimental capacity that can be standardized, automated, and called on demand by scientists, software, and AI agents.
From startup to unicorn
MegaRobo was founded in 2016, which makes it about a decade old — old enough to have survived several funding cycles, and young enough that its best-known product categories are still new. Its path to scale ran through a large Series C in June 2022, a round of nearly $300 million co-led by Goldman Sachs Alternatives, Asia Investment Capital, and Granite Asia, with participation from Pavilion Capital, part of Temasek's Seviora Group. That round lifted the company's valuation above $1 billion, making it a unicorn, and it remains the largest single round in the company's history. The new round, at nearly $200 million, is the second-largest.
The investor list around that Series C is worth noting because it shows how MegaRobo has been financed. Long-term investors such as Sinovation Ventures, Joy Capital, and MPCi have supported the company through multiple stages. Earlier industry investors include WuXi AppTec, one of China's largest drug research and manufacturing organizations, and Bosch Ventures, the venture arm of the German industrial group. That combination — financial investors, a drug industry strategic investor, and an industrial automation strategic investor — mirrors the company's own hybrid identity, sitting between software, hardware, and science.
Total funding of approximately $600 million across multiple rounds puts MegaRobo in the upper tier of Chinese AI companies by capital raised, though it is far from the largest. What distinguishes it is the customer base. More than 500 customers, including leading global pharmaceutical companies, is a commercial footprint that many AI drug discovery companies cannot match. The company's continued expansion across North America, Europe, the Middle East, and Asia, as described in its own statement, suggests that footprint is now genuinely international rather than concentrated in China alone.
The Hong Kong listing waiting game
One of the most important facts about MegaRobo is also one of the least discussed in the funding announcement: the company filed for a Hong Kong initial public offering in mid-2025, and founder and chief executive Daniel Huang has said the company remains in the queue. That filing changes how this funding round should be read. A company that has already filed to go public and then raises nearly $200 million privately is not raising a routine growth round. It is either strengthening its balance sheet ahead of a listing, buying time while market conditions improve, or both.
Hong Kong's IPO market has been uneven for Chinese technology companies in recent years, and the queue for listings is long. A company in the queue faces a choice: wait for the window to open, or raise privately to keep growing while it waits. MegaRobo appears to have chosen the second path, and the composition of the round supports that reading. A sovereign wealth fund and a bank-affiliated investor are exactly the kind of patient, large-scale capital that can fund a company through a long pre-IPO period without demanding the quick exit a venture fund might need. The existing investors re-upping also signals that the current shareholders would rather fund the company privately than push it into a weak public market.
For founders watching this deal, the lesson is about sequencing. MegaRobo did not rush to list, and it did not let the IPO filing stop it from raising private capital. The nearly $200 million gives it room to keep investing in technology and expansion without being forced to accept whatever valuation the public market offers on a given day. If and when the Hong Kong listing happens, the company will arrive with a larger balance sheet, more customers, and a more international footprint than it had when it first filed. That is a stronger position than filing and then standing still.
What the money is for
The stated uses of the new money are broad: core technology, global expansion of the AI for Science business, and infrastructure for AI in complex physical environments. Reading between the lines, three priorities stand out. The first is the One Intelligence Stack itself, which is a platform bet that requires sustained engineering investment across software, robotics, and scientific instruments. Platforms of that kind are expensive to build and hard to copy once they work, which is why the company frames its technology as infrastructure rather than a collection of applications.
The second priority is geographic expansion, and here the investor list is the clue. A round joined by Oman's sovereign fund points toward the Middle East as a real focus, not just a line in a press release. The Gulf states are investing heavily in biotechnology, life sciences, and AI, and they are building research capacity from scratch, which makes them natural customers for a company that sells the infrastructure of science itself. North America and Europe matter too, because that is where the largest pharmaceutical companies are, and MegaRobo already counts leading global drugmakers among its customers. The challenge will be serving those markets while navigating export controls, data rules, and political scrutiny that now surround Chinese technology companies operating abroad.
The third priority is the scientific community itself, through efforts like Poreva Open. Wet-lab validation for more than 10,000 protein design sequences is not cheap, and it is not a direct revenue generator. It is an investment in making MegaRobo's platform the place where AI protein design gets tested against reality, which in turn makes the platform more valuable to every customer and partner. That kind of spending only makes sense for a company that believes its advantage is infrastructure, not any single model, and that is willing to pay to set the standard the rest of the field is measured against.
Why this round matters for AI investors
For investors, MegaRobo's round is a data point on a question that has divided the AI market for two years: where does the durable value sit? The first wave of AI funding went to model builders and to software that wraps models in chat interfaces. The second wave is now moving toward companies that connect AI to the physical world — robots, laboratories, factories, and instruments — where the feedback loop between intelligence and execution creates data that no competitor can easily replicate. MegaRobo is a pure play on that second wave, and the fact that it could raise nearly $200 million with a sovereign wealth fund aboard suggests that sophisticated capital agrees with the thesis.
There is also a geographic signal. Chinese AI companies have faced a harder fundraising environment since 2022, as Western investors pulled back and geopolitical tensions rose. A round of this size, with new money from the Gulf and from a Chinese bank-affiliated investor, shows that capital is still available for Chinese technology companies with real products and real customers — it is just coming from different sources than it did five years ago. For founders in China, that is a meaningful shift in the funding map. For investors elsewhere, it is a reminder that the AI for Science race is global, and that the infrastructure layer may be built by companies they have not been watching.
The risks are real and should not be minimized. MegaRobo did not disclose its valuation, so it is impossible to know whether this round was flat, up, or down from the above-$1 billion mark set in 2022. A company that raises nearly $200 million without disclosing valuation invites that question, and the answer will only become clear if and when the Hong Kong listing prices. The company also operates in one of the most politically exposed corners of technology: Chinese AI, applied to drug discovery, with ambitions to expand in the United States and Europe. Export controls, investment screening, and customer caution about Chinese technology could all slow that expansion, however good the products are.
What to watch next
The first thing to watch is whether MegaRobo discloses more about the round — an exact figure, a valuation, or a named lead — in filings connected to its Hong Kong listing. Listing documents will eventually force that disclosure, and the numbers there will tell investors whether the private market still values the company above its 2022 unicorn mark. The second is the pace of the IPO itself. A company that has been in the queue since mid-2025 and has just raised nearly $200 million privately is not in a hurry, but the queue does not last forever, and the listing, when it comes, will be the first public test of the AI for Science infrastructure thesis.
The third is execution on the ground: whether Megalaxy Lab keeps adding customers beyond the 200 it already serves, whether Poreva Open produces results that the research community takes seriously, and whether the Middle East expansion turns into signed customers rather than conference appearances. The fourth is the competitive picture. AI drug discovery is crowded, with well-funded companies in the United States, Europe, and China all racing to automate different parts of the pipeline. MegaRobo's bet is that owning the physical infrastructure — the robots, the labs, the validation — matters more than owning any single model. The next two years, funded by this round, will show whether that bet pays off.
Angeled.com connects founders with investors.
PR Newswire
Tech in Asia
VC Post
AI Weekly
AlphaMaven
AsiaTechTimes
Read Next
Soufflé Therapeutics Raises $135M Series B to Push Cell-Specific RNA Medicines Into the Clinic
Space Startup Funding 2026: Startups Raise Record $20.8 Billion in Q3
seragy Raises €12M to Advance Quantitative Biomarkers for Neurodegenerative Disease Drug Development
AI Biopharma's Infrastructure Turn: The Money Is Moving Down the Stack
Avarra Raises $17M Series A to Upskill Sales Teams With AI Avatars
CarbonFarm Raises €7M Series A to Tackle Methane Emissions From Rice Farming



